Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 8/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29082317 | 0.87 | POLB (0.56) | GAASMN1; SMN2HTTALDH1A1RAB9A | |
| SCHEMBL29082301 | 0.87 | SMN1; SMN2 (0.72) | GAASMN1; SMN2HTTALDH1A1TDP1 | |
| SCHEMBL25397951 | 0.87 | GAA (0.66) | GAASMN1; SMN2HTTALDH1A1TDP1 | |
| SCHEMBL1222782 | 0.87 | SMN1; SMN2 (0.57) | GAASMN1; SMN2HTTALDH1A1RAB9A | |
| SCHEMBL11488796 | 0.86 | PLK1 (0.59) | GAASMN1; SMN2ALDH1A1TDP1RAB9A | |
| SCHEMBL25393959 | 0.84 | SMN1; SMN2 (0.49) | GAASMN1; SMN2HTTALDH1A1TDP1 | |
| SCHEMBL16399046 | 0.84 | NPSR1 (0.53) | GAASMN1; SMN2HTTALDH1A1TDP1 | |
| SCHEMBL17213095 | 0.84 | ALDH1A1 (0.59) | GAASMN1; SMN2HTTALDH1A1TDP1 | |
| SCHEMBL11479178 | 0.83 | GAA (0.51) | GAASMN1; SMN2HTTALDH1A1TDP1 | |
| SCHEMBL25837760 | 0.81 | SMN1; SMN2 (0.62) | GAASMN1; SMN2HTTALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197363-A1 | THIADIAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, INCLUDING SAME | CUREVERSE INCORPORATED (KR) | 2025-06-19 | — | — | US | disclosed |
| EP-4495106-A1 | THIADIAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, INCLUDING SAME | Daegu-Gyeongbuk Medical Innovation Foundation (KR) | 2025-01-22 | — | — | EP | disclosed |
| CN-119212981-A | Thiadiazole compound and pharmaceutical composition for preventing or treating inflammatory diseases comprising the same | 财团法人 大邱庆北尖端医疗产业振兴财团 | 2024-12-27 | — | — | CN | disclosed |
| WO-2023177146-A1 | THIADIAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, INCLUDING SAME | 재단법인 대구경북첨단의료산업진흥재단 | 2023-09-21 | — | — | WO | disclosed |
| EP-2590969-B1 | Therapeutic agents 976 | ASTRAZENECA AB (SE) | 2014-10-15 | — | — | EP | disclosed |
| EP-2590969-B1 | Therapeutic agents 976 | ASTRAZENECA AB (SE) | 2014-10-15 | — | — | EP | disclosed |
| US-8546375-B2 | (3-(4-(aminomethyl)phenoxy or phenylthio)azetidin-1-yl)(5-phenyl-1,3,4-oxadiazol-2-yl)methanone compounds | ASTRAZENECA AB (SE) | 2013-10-01 | — | — | US | disclosed |
| US-8546375-B2 | (3-(4-(aminomethyl)phenoxy or phenylthio)azetidin-1-yl)(5-phenyl-1,3,4-oxadiazol-2-yl)methanone compounds | ASTRAZENECA AB (SE) | 2013-10-01 | — | — | US | disclosed |
| CN-103209979-A | Therapeutic agent 976 | ASTRAZENECA AB | 2013-07-17 | — | — | CN | disclosed |
| EP-2590969-A2 | THERAPEUTIC AGENTS 976 | AstraZeneca AB (SE) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012004588-A2 | THERAPEUTIC AGENTS 976 | ASTRAZENECA AB (SE) | 2012-01-12 | — | — | WO | disclosed |
| US-20120010189-A1 | (3-(4-(AMINOMETHYL)PHENOXY OR PHENYLTHIO)AZETIDIN-1-YL)(5-PHENYL-1,3,4-OXADIAZOL-2-YL)METHANONE COMPOUNDS | ASTRAZENECA AB (SE) | 2012-01-12 | — | — | US | disclosed |
| US-20120010189-A1 | (3-(4-(AMINOMETHYL)PHENOXY OR PHENYLTHIO)AZETIDIN-1-YL)(5-PHENYL-1,3,4-OXADIAZOL-2-YL)METHANONE COMPOUNDS | ASTRAZENECA AB (SE) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197363-A1 | THIADIAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, INCLUDING SAME | PPARD, PPARG, PPARA | GAA 3367/4885SMN1; SMN2 4715/4885HTT 3965/4885 |
| US-20120010189-A1 | (3-(4-(AMINOMETHYL)PHENOXY OR PHENYLTHIO)AZETIDIN-1-YL)(5-PHENYL-1,3,4-OXADIAZOL-2-YL)METHANONE COMPOUNDS | TYR, MC2R, MC1R | GAA 495/4885SMN1; SMN2 1767/4885HTT 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.